{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:13:43Z","timestamp":1759331623109,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jfo.2018.03.014","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T03:38:27Z","timestamp":1540006707000},"page":"789-801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypertonie intraoculaire retard\u00e9e li\u00e9e aux injections intra-vitr\u00e9ennes r\u00e9p\u00e9t\u00e9es d\u2019anti-VEGF\u00a0: des cas n\u00e9cessitant une chirurgie filtrante"],"prefix":"10.1016","volume":"41","author":[{"given":"I.","family":"Leleu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Penaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Blumen-Ohana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Rodallec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Laplace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Akesbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Nordmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2018.03.014_bib0230","first-page":"126","article-title":"Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product","volume":"211","author":"Polansky","year":"1997","journal-title":"Ophthalmol J Int"},{"key":"10.1016\/j.jfo.2018.03.014_bib0235","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jfo.2012.02.009","article-title":"Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections","volume":"35","author":"El Chehab","year":"2012","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0240","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.eye.6702938","article-title":"Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab","volume":"23","author":"Bakri","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2018.03.014_bib0245","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00417-008-0819-2","article-title":"Persisent ocular hypertension following intravitreal ranibizumab","volume":"246","author":"Bakri","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0250","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jfo.2017.01.003","article-title":"Ocular hypertension after intravitreal injection: screening and management","volume":"40","author":"Poli","year":"2017","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0255","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3928\/15428877-20120618-01","article-title":"Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections","volume":"43","author":"Skalicky","year":"2012","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.jfo.2018.03.014_bib0260","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/IJG.0b013e31820d7d19","article-title":"Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration","volume":"21","author":"Tseng","year":"2012","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jfo.2018.03.014_bib0265","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2013.11.029","article-title":"Intraocular pressure in eyes receiving monthly ranibizumab in 2\u00a0pivotal age-related macular degeneration clinical trials","volume":"121","author":"Bakri","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2018.03.014_bib0270","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","article-title":"Safety of intravitreal dexamethasone implant (OZURDEX): the SAFODEX study. Incidence and risk factors of ocular hypertension","volume":"37","author":"Malcl\u00e8s","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2018.03.014_bib0275","first-page":"43","article-title":"Intraocular pressure spikes after aflibercept intravitreal injections","volume":"236","author":"El Chehab","year":"2016","journal-title":"Ophthalmol J Int"},{"key":"10.1016\/j.jfo.2018.03.014_bib0280","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/eye.2014.180","article-title":"Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients","volume":"28","author":"Murray","year":"2014","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2018.03.014_bib0285","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ajo.2007.01.052","article-title":"Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma","volume":"143","author":"Frenkel","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0290","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/IJG.0b013e31819c4893","article-title":"Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure","volume":"18","author":"Gismondi","year":"2009","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jfo.2018.03.014_bib0295","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1055\/s-0029-1245201","article-title":"Effect of brimonidine\/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab","volume":"227","author":"Theoulakis","year":"2010","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.jfo.2018.03.014_bib0300","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcjo.2014.11.004","article-title":"Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma","volume":"50","author":"Agard","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0305","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2018.03.014_bib0310","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2018.03.014_bib0315","series-title":"Presented as a scientific paper at the AAO Annual meeting","article-title":"IOP in eyes treated with monthly ranibizumab: a post-hoc analysis of data from MARINA et ANCHOR trials","author":"Bakri","year":"2010"},{"key":"10.1016\/j.jfo.2018.03.014_bib0320","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00417-012-1981-0","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration","volume":"250","author":"Mathalone","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0325","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/jop.2009.0076","article-title":"Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections","volume":"26","author":"Adelman","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2018.03.014_bib0330","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents","volume":"95","author":"Good","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0335","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/15569527.2015.1124886","article-title":"Long-term intraocular pressure changes after intravitreal injection of bevacizumab","volume":"35","author":"Baek","year":"2016","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0340","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3928\/23258160-20130909-07","article-title":"Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents","volume":"44","author":"Pershing","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jfo.2018.03.014_bib0345","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14728214.2017.1362390","article-title":"Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration","volume":"22","author":"Hussain","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.jfo.2018.03.014_bib0350","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2018.03.014_bib0355","first-page":"514","article-title":"New treatment modalities for neovascular age-related macular degeneration","volume":"6","author":"Schlottmann","year":"2017","journal-title":"Asia-Pac J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0360","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/ICU.0000000000000036","article-title":"The link between intravitreal antivascular endothelial growth factor injections and glaucoma","volume":"25","author":"SooHoo","year":"2014","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0365","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5301\/ejo.5000159","article-title":"Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection","volume":"23","author":"El Chehab","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0370","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874364101004010028","article-title":"Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis","volume":"4","author":"Sniegowski","year":"2010","journal-title":"Open Ophthalmol J"},{"key":"10.1016\/j.jfo.2018.03.014_bib0375","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/IAE.0b013e31816c6868","article-title":"Intravitreal silicone oil droplets after intravitreal drug injections","volume":"28","author":"Bakri","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2018.03.014_bib0380","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamaophthalmol.2017.1815","article-title":"Incidence of presumed silicone oil droplets in the vitreous cavity after intravitreal bevacizumab injection with insulin syringes","volume":"135","author":"Khurana","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0385","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/jop.2014.0062","article-title":"High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism","volume":"31","author":"Ricca","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2018.03.014_bib0390","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2018.03.014_bib0395","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2018.03.014_bib0400","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3928\/15428877-20090430-12","article-title":"Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections","volume":"40","author":"Kahook","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.jfo.2018.03.014_bib0405","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/IAE.0b013e318217ffde","article-title":"Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib","volume":"31","author":"Choi","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2018.03.014_bib0410","first-page":"352","article-title":"Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab","volume":"15","author":"Segal","year":"2013","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.jfo.2018.03.014_bib0415","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/sj.eye.6703018","article-title":"Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication","volume":"21","author":"Jalil","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2018.03.014_bib0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2014.02.035","article-title":"Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure","volume":"157","author":"Kim","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0425","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s00417-017-3782-y","article-title":"Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting","volume":"255","author":"Vo Kim","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2018.03.014_bib0430","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/IAE.0b013e31823f0c95","article-title":"A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab","volume":"32","author":"Wehrli","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2018.03.014_bib0435","doi-asserted-by":"crossref","first-page":"39301","DOI":"10.1038\/srep39301","article-title":"Sustained elevation of intraocular pressure associated with intravitreal administration of anti-vascular endothelial growth factor: a systematic review and meta-analysis","volume":"6","author":"Zhou","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfo.2018.03.014_bib0440","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00061198-200206000-00009","article-title":"Deep sclerectomy with collagen implant in one eye compared with trabeculectomy in the other eye of the same patient","volume":"11","author":"Ambresin","year":"2002","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jfo.2018.03.014_bib0445","first-page":"CD007059","article-title":"Non-penetrating filtration surgery versus trabeculectomy for open-angle glaucoma","volume":"2","author":"Eldaly","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfo.2018.03.014_bib0225","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaophthalmol.2017.0059","article-title":"Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery","volume":"135","author":"Eadie","year":"2017","journal-title":"JAMA Ophthalmol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551218303656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551218303656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:09:00Z","timestamp":1759259340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551218303656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0181551218303656"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2018.03.014","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertonie intraoculaire retard\u00e9e li\u00e9e aux injections intra-vitr\u00e9ennes r\u00e9p\u00e9t\u00e9es d\u2019anti-VEGF\u00a0: des cas n\u00e9cessitant une chirurgie filtrante","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2018.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}